PCM
PRLD icon

Pinz Capital Management’s Prelude Therapeutics PRLD Stock Holding History

Pinz Capital Management’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-43,800
Closed -$545K – 197
2021
Q4 		$545K Buy
+43,800
New +$713K 0.21% 133
2020
Q4 		– Sell
-31,101
Closed -$937K – 178
2020
Q3 		$937K Buy
+31,101
New +$878K 0.34% 65

Other funds holding PRLD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pinz Capital Management's PRLD Position: Q1 2022 in Review

Pinz Capital Management sold out of Prelude Therapeutics (PRLD) in Q1 2022, closing a stake of 43,800 shares — an estimated $545K sold.

Pinz Capital Management first reported a position in PRLD in Q3 2020 and held it in 2 quarters. The position peaked at $937K in Q3 2020. 68 funds tracked by Wall St. Rank hold PRLD as of Q1 2022.

  • Pinz Capital Management reported no remaining Prelude Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Pinz Capital Management sold 43,800 Prelude Therapeutics shares in Q1 2022, an estimated $545K.
  • Pinz Capital Management first reported a position in Prelude Therapeutics in Q3 2020 and held it in 2 quarters.
  • Pinz Capital Management's Prelude Therapeutics position peaked at $937K in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2022.

Based on Pinz Capital Management's 13F filing for Q1 2022, filed 16 May 2022.